NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

Last update: 20 hours ago

49.12

-0.25 (-0.51%)

  • 1D -0.51%
  • 5D -2.35%
  • 1M -17.94%
  • 6M -1.50%
  • YTD -6.24%
  • 1Y -41.34%
  • 5Y 32.88%
Previous Close 49.37
Open 50.02
Volume 15,822,448
Avg. Volume (3M) 22,123,605
Market Cap 218,422,738,944
Price / Earnings (TTM) 13.53
Price / Earnings (Forward) 13.18
Price / Sales 4.49
Price / Book 7.15
52 Weeks Range
43.08 (-12%) — 93.80 (90%)
Earnings Date 6 May 2026
TTM Dividend Yield 2.24%
Profit Margin 34.51%
Operating Margin (TTM) 49.68%
Diluted EPS (TTM) 3.67
Quarterly Revenue Growth (YOY) 19.50%
Quarterly Earnings Growth (YOY) 14.30%
Total Debt/Equity (MRQ) 85.70%
Current Ratio (MRQ) 0.740
Operating Cash Flow (TTM) 131.24 B
Levered Free Cash Flow (TTM) 77.73 B
Return on Assets (TTM) 23.29%
Return on Equity (TTM) 88.12%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Bullish
Drug Manufacturers - General (Global) Bullish Bullish
Stock Novo Nordisk A/S Bullish Bearish

AIStockmoo Score

1.1
Analyst Consensus 1.5
Insider Activity NA
Price Volatility 4.5
Technical Moving Averages 1.0
Technical Oscillators -2.5
Average 1.13

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
NVO 218 B 2.24% 13.53 7.15
NVS 302 B 3.27% 21.88 6.47
LLY 919 B 0.15% 45.45 39.30
JNJ 580 B 0.52% 21.81 7.24
ABBV 395 B 0.73% 94.27 50.46
MRK 293 B 0.69% 16.16 5.55

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Core
% Held by Insiders 0.01%
% Held by Institutions 9.85%

Ownership

Name Date Shares Held
Fayez Sarofim & Co 30 Sep 2025 7,353,587
Everett Harris & Co /Ca/ 30 Sep 2025 6,393,780
52 Weeks Range
43.08 (-12%) — 93.80 (90%)
Price Target Range
46.00 (-6%) — 73.50 (49%)
High 73.50 (CICC, 49.63%) Buy
Median 54.00 (9.94%)
Low 46.00 (BMO Capital, -6.35%) Hold
Average 57.83 (17.73%)
Total 2 Buy, 1 Hold
Avg. Price @ Call 51.74
Firm Date Target Price Call Price @ Call
CICC 09 Jan 2026 73.50 (49.63%) Buy 58.81
Goldman Sachs 28 Nov 2025 54.00 (9.93%) Buy 49.35
BMO Capital 25 Nov 2025 46.00 (-6.35%) Hold 47.06

No data within this time range.

  • 3M
Date Type Details
11 Feb 2026 CNBC Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start
11 Feb 2026 CNBC Novo Nordisk CEO sees 15 million patient opportunity in Medicare coverage for obesity drugs
09 Feb 2026 CNBC FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims
09 Feb 2026 CNBC Super Bowl 60 recap: Rewatch all the top commercials from advertising's biggest night
09 Feb 2026 CNBC Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock falls 18%
06 Feb 2026 CNBC White House launches direct-to-consumer drug site TrumpRx. Here's what to know
05 Feb 2026 Announcement Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers
05 Feb 2026 Announcement Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
05 Feb 2026 Announcement Lexaria Announces Positive Final Results From Human Pilot Study #5
04 Feb 2026 Announcement Novo Nordisk initiates 2026 share repurchase programme
04 Feb 2026 CNBC Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
04 Feb 2026 CNBC Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
04 Feb 2026 Announcement Novo Nordisk has published its annual report for 2025
04 Feb 2026 Announcement Novo Nordisk files annual report with the SEC
03 Feb 2026 Announcement Novo Nordisk releases 2026 sales and operating profit outlook
03 Feb 2026 CNBC Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
03 Feb 2026 Announcement Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025
02 Feb 2026 Announcement Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
31 Jan 2026 Announcement New employee representative on the Board of Directors of Novo Nordisk A/S
30 Jan 2026 CNBC Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch
30 Jan 2026 CNBC Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections
23 Jan 2026 CNBC What obesity drugmakers see next in the market: More pills, easier access and drug combinations
20 Jan 2026 Announcement Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes
20 Jan 2026 CNBC Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
16 Jan 2026 CNBC Novo Nordisk shares rise 8% after Wegovy obesity pill has 'solid' launch
10 Jan 2026 CNBC 2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
09 Jan 2026 CNBC Amazon Pharmacy starts offering Novo Nordisk's Wegovy weight loss pill
05 Jan 2026 CNBC First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. 
05 Jan 2026 Announcement Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
31 Dec 2025 Announcement Novo Nordisk A/S: China’s Supreme People’s Court delivers a positive ruling on the semaglutide compound patent
22 Dec 2025 Announcement Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
22 Dec 2025 CNBC FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
19 Dec 2025 CNBC Wall Street banked on a flurry of deals under Trump in 2025. It wasn't that simple
12 Dec 2025 Announcement Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss
11 Dec 2025 CNBC Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial  
09 Dec 2025 Announcement Novo Nordisk has completed its acquisition of Akero Therapeutics
01 Dec 2025 CNBC Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
25 Nov 2025 Announcement Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes
24 Nov 2025 Announcement Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression
24 Nov 2025 CNBC Eli Lilly hits $1 trillion market value, a first in health care, as Novo Nordisk tumbles
17 Nov 2025 Announcement Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
17 Nov 2025 CNBC Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
14 Nov 2025 Announcement Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S
13 Nov 2025 Announcement Novo Nordisk A/S: Candidate for the Board of Directors will not seek election
11 Nov 2025 Announcement Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Show more
TTM Dividend Yield 2.24%
5Y Average Dividend Yield 2.17%
Payout Ratio 47.09%
Ex Date Announcement Date Payment Date Details
31 Mar 2025 05 Feb 2025 08 Apr 2025 1.099206 Cash
16 Aug 2024 06 Aug 2024 26 Aug 2024 0.5126402 Cash
22 Mar 2024 31 Jan 2024 02 Apr 2024 0.92985 Cash
18 Aug 2023 10 Aug 2023 29 Aug 2023 0.8835613 Cash
24 Mar 2023 02 Feb 2023 04 Apr 2023 1.1887415 Cash
12 Aug 2022 04 Aug 2022 23 Aug 2022 0.5835507 Cash
25 Mar 2022 02 Mar 2022 05 Apr 2022 1.022423 Cash
16 Aug 2021 - 25 Aug 2021 0.5502889 Cash
26 Mar 2021 - 07 Apr 2021 0.922122 Cash
14 Aug 2020 06 Aug 2020 25 Aug 2020 0.5177774 Cash
27 Mar 2020 06 Feb 2020 07 Apr 2020 0.7826048 Cash
16 Aug 2019 10 Aug 2019 27 Aug 2019 0.449438 Cash
22 Mar 2019 05 Feb 2019 02 Apr 2019 0.777006 Cash
17 Aug 2018 09 Aug 2018 28 Aug 2018 0.462327 Cash
23 Mar 2018 24 Mar 2018 03 Apr 2018 0.805982 Cash
17 Aug 2017 - 29 Aug 2017 0.33589 Cash
23 Mar 2017 - 04 Apr 2017 0.479369 Cash
11 Aug 2016 - 23 Aug 2016 0.331026 Cash
18 Mar 2016 - 30 Mar 2016 0.69943 Cash
19 Mar 2015 - 31 Mar 2015 0.532885 Cash
21 Mar 2014 - 02 Apr 2014 0.606122 Cash
21 Mar 2013 - 02 Apr 2013 2.264307 Cash
22 Mar 2012 - 03 Apr 2012 1.831902 Cash
24 Mar 2011 - 05 Apr 2011 1.357901 Cash
25 Mar 2010 - 07 Apr 2010 0.978615 Cash
19 Mar 2009 - 31 Mar 2009 0.781532 Cash
13 Mar 2008 - 25 Mar 2008 0.678462 Cash
08 Mar 2007 - 20 Mar 2007 0.891779 Cash
09 Mar 2006 - 21 Mar 2006 0.691753 Cash
10 Mar 2005 - 22 Mar 2005 0.61725 Cash
17 Mar 2004 - 29 Mar 2004 0.52096 Cash
26 Mar 2003 - 07 Apr 2003 0.37647 Cash
13 Mar 2002 - 25 Mar 2002 0.2848 Cash
21 Mar 2001 - 02 Apr 2001 0.5681 Cash
24 Mar 2000 - 06 Apr 2000 0.4672 Cash
25 Mar 1999 - 06 Apr 1999 0.4182 Cash
27 Mar 1998 - 08 Apr 1998 0.3051 Cash
25 Apr 1997 - 07 May 1997 0.239 Cash
01 May 1996 - 14 May 1996 0.1806 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 1.10 1 2.16
2024 1.44 2 1.68
2023 2.07 2 2.00
2022 1.61 2 2.37
2021 1.47 2 2.63
2020 1.30 2 3.72
2019 1.23 2 4.24
2018 1.27 2 5.51
2017 0.815 2 3.04
2016 1.03 2 5.75
2015 0.533 1 1.84
2014 0.606 1 2.86
2013 2.26 1 12.26
2012 1.83 1 11.22
2011 1.36 1 11.78
2010 0.979 1 8.69
2009 0.782 1 12.24
2008 0.678 1 13.20
2007 0.892 1 13.75
2006 0.692 1 16.54
2005 0.617 1 21.94
2004 0.521 1 19.20
2003 0.376 1 18.38
2002 0.285 1 19.71
2001 0.568 1 28.33
2000 0.467 1 26.40
1999 0.418 1 32.36
1998 0.305 1 22.94
1997 0.239 1 16.57
1996 0.181 1 19.32
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria